The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Innovative lead discovery strategies for tropical diseases
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome sequence of the human malaria parasite Plasmodium falciparum
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002) · Nature · doi:10.1038/nature01097 · Cited by 4,407
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Anti-infective potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’
Cos, P., Vlietinck, A. J., Berghe, D. V., & Maes, L. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.04.003 · Cited by 1,603
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
The Process of Structure-Based Drug Design
Anderson, A. C. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.09.002 · Cited by 939
Integration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
Drug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Antimalarial drug discovery: efficacy models for compound screening
Fidock, D. A., Rosenthal, P. J., Croft, S. L., Brun, R., & Nwaka, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1416 · Cited by 861
Self-citationComparative Genomics of Trypanosomatid Parasitic Protozoa
El-Sayed, N. M., Myler, P. J., Blandin, G., Berriman, M., Crabtree, J., Aggarwal, G., Caler, E., Renauld, H., Worthey, E. A., Hertz-Fowler, C., et al. (2005) · Science · doi:10.1126/science.1112181 · Cited by 819
Hotez, P. J., Molyneux, D. H., Fenwick, A., Ottesen, E., Ehrlich Sachs, S., & Sachs, J. D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030102 · Cited by 817
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Identification of an antimalarial synthetic trioxolane drug development candidate
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C. K., Chollet, J., Dong, Y., Dorn, A., Hunziker, D., Matile, H., et al. (2004) · Nature · doi:10.1038/nature02779 · Cited by 622
Computational methods for the prediction of ‘drug-likeness’
Clark, D. E., & Pickett, S. D. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01451-8 · Cited by 578
Opportunities and Challenges in Antiparasitic Drug Discovery
Pink, R., Hudson, A., Mouriès, M.-A., & Bendig, M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1824 · Cited by 545
Self-citationHigh-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Insights into antifolate resistance from malarial DHFR-TS structures
Yuvaniyama, J., Chitnumsub, P., Kamchonwongpaisan, S., Vanichtanankul, J., Sirawaraporn, W., Taylor, P., Walkinshaw, M. D., & Yuthavong, Y. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb921 · Cited by 419
PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data
Bahl, A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg081 · Cited by 371
A clinical drug library screen identifies astemizole as an antimalarial agent
Chong, C. R., Chen, X., Shi, L., Liu, J. O., & Sullivan, D. J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio806 · Cited by 289
The life and times of ivermectin — a success story
Õmura, S., & Crump, A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1048 · Cited by 273
Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase
Kuo, M. R., Morbidoni, H. R., Alland, D., Sneddon, S. F., Gourlie, B. B., Staveski, M. M., Leonard, M., Gregory, J. S., Janjigian, A. D., Yee, C., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211968200 · Cited by 263
Virtual drug discovery and development for neglected diseases through public–private partnerships
Nwaka, S., & Ridley, R. G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1230 · Cited by 260
Self-citationHealth Innovation Networks to Help Developing Countries Address Neglected Diseases
Morel, C. M., Acharya, T., Broun, D., Dangi, A., Elias, C., Ganguly, N. K., Gardner, C. A., Gupta, R. K., Haycock, J., Heher, A. D., et al. (2005) · Science · doi:10.1126/science.1115538 · Cited by 236
Antibiotics: Where did we go wrong?
Overbye, K. M., & Barrett, J. F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03285-4 · Cited by 223
A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need
Moran, M. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020302 · Cited by 198
Baldwin, J., Michnoff, C. H., Malmquist, N. A., White, J., Roth, M. G., Rathod, P. K., & Phillips, M. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501100200 · Cited by 197
High-throughput drug discovery: What can we expect from HTS?
Gribbon, P., & Andreas, S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03275-1 · Cited by 174
Barr, S. C., Warner, K. L., Kornreic, B. G., Piscitelli, J., Wolfe, A., Benet, L., & McKerrow, J. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5160-5161.2005 · Cited by 170
PlasmoDB: The Plasmodium Genome Resource
Whetzel, P. L., Date, S. V., Essien, K., Fraunholz, M. J., Gajria, B., Grant, G. R., Iodice, J., Kissinger, J. C., Labo, P. T., Milgram, A. J., et al. (2014) · Molecular Approaches to Malaria · doi:10.1128/9781555817558.ch2 · Cited by 165
Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis
Hasan, S., Daugelat, S., Rao, P. S. S., & Schreiber, M. (2006) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020061 · Cited by 159
Comparative genomics of nematodes
Mitreva, M., Blaxter, M., Bird, D. M., & McCarter, J. P. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.08.003 · Cited by 145
The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans
Cotreau, M. M., Warren, S., Ryan, J. L., Fleckenstein, L. L., Vanapalli, S. R., Brown, K. R., Rock, D., Chen, C., & Schwertschlag, U. S. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003257456 · Cited by 137
Chemistry-to-gene screens in Caenorhabditis elegans
Jones, A. K., Buckingham, S. D., & Sattelle, D. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1692 · Cited by 130
Taking inventory: antibacterial agents currently at or beyond Phase 1
Bush, K., Macielag, M. J., & Weidner‐Wells, M. A. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.013 · Cited by 126
Andrews, K. T., Walduck, A. K., Kelso, M. J., Fairlie, D. P., Saul, A. J., & Parsons, P. G. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00043-6 · Cited by 116
New estimates of drug development costs
Frank, R. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(03)00002-x · Cited by 115
Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei
Mackey, Z. B., Baca, A. M., Mallari, J. P., Apsel, B., Shelat, A. A., Hansell, E. J., Chiang, P. K., Wolff, B. E., Guy, R. K., Williams, J. A., et al. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00389.x · Cited by 106
Strategic emphases for tropical diseases research: a TDR perspective
Remme, J. H. F., Blas, E., Chitsulo, L., Desjeux, P. M. P., Engers, H. D., Kanyok, T. P., Kengeya‐Kayondo, J. F., Kioy, D. W., Kumaraswami, V., Lazdins, J. K., et al. (2002) · Trends in Parasitology · doi:10.1016/s1471-4922(02)02387-5 · Cited by 102
Nwaka, S. (2005) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2005.06.003 · Cited by 56
Self-citationSturk, L. M., Brock, J. L., Bagnell, C. R., Hall, J. E., & Tidwell, R. R. (2004) · Acta Tropica · doi:10.1016/j.actatropica.2004.03.010 · Cited by 46
TDR collaboration with the pharmaceutical industry
Gutteridge, W. E. (2006) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/j.trstmh.2006.02.013 · Cited by 32
Invited Perspective: High-Throughput Screening in Academia: The Harvard Experience
Stein, R. L. (2003) · SLAS DISCOVERY · doi:10.1177/1087057103260741 · Cited by 31
Research on infectious diseases requires better coordination
Ridley, R. G. (2004) · Nature Medicine · doi:10.1038/nm1153 · Cited by 24
Cited by
Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., & Wyatt, P. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200700139 · Cited by 709
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Kinetoplastids: related protozoan pathogens, different diseases
Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gürtler, R. E., McKerrow, J., Reed, S., & Tarleton, R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33945 · Cited by 604
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Drug repurposing and human parasitic protozoan diseases
Andrews, K. T., Fisher, G., & Skinner-Adams, T. S. (2014) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.02.002 · Cited by 383
Metadata
- Authors
- Nwaka, S., & Hudson, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-11
- Volume
- 5
- Issue
- 11
- Pages
- 941-955
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2070854001
- Cited by
- 521
- References
- 44
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.